PREVENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS; TASK ORDER TITLE: PRECLINICAL DEVELOPMENT OF AN RNA VACCINE FOR IMMUNOPREV

NIH Pandemic-Era Grants

Pandemic Era Grants

2024

↗ Live URL (may be dead)

Document text

Principal Investigator: DAVID  MCCORMICK
Organization: IIT RESEARCH INSTITUTE
Fiscal Year: 2024
Award: $1,020,618
Funding agency: National Cancer Institute

PRECLINICAL DEVELOPMENT OF AN RNA VACCINE FOR IMMUNOPREVENTION OF PROSTATE CANCER

Terms: <Androgenic Agents><Androgenic Compounds><Androgens><Animals><Biological Markers><Cancers><Evaluation><Experimental Models><Genes><Immunoprevention><Malignant><Malignant - descriptor><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Prostate><Malignant neoplasm of prostate><Malignant prostatic tumor><Preventive><Prostate><Prostate CA><Prostate Cancer><Prostate Gland><Prostate malignancy><Prostatic Cancer><Prostatic Gland><RNA vaccine><RNA-based vaccine><Regimen><Risk><Target Populations><Therapeutic Androgen><Vaccination><Vaccines><bio-markers><biologic marker><biomarker><immunogenicity><mRNA vaccine><mRNA-based vaccine><malignancy><men><neoplasm/cancer><pre-clinical development><pre-clinical efficacy><preclinical development><preclinical efficacy><prevent><preventing><programs><prostate cancer model><prostate tumor model><tumor>